Interferon Regulatory Factor Signalings in Cardiometabolic Diseases

Hypertension

Volumn 66, Issue 2, 2015, Pages 222-247

  Zhang, Xiao Jing ^a,b,c   Zhang, Peng ^a,b   Li, Hongliang ^a,b  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

^c University of Macau   (Macao)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSOL RECEPTOR; INTERFERON; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERFERON REGULATORY FACTOR; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 2; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 4; INTERFERON REGULATORY FACTOR 5; INTERFERON REGULATORY FACTOR 6; INTERFERON REGULATORY FACTOR 7; INTERFERON REGULATORY FACTOR 9; PATTERN RECOGNITION RECEPTOR;

BLOOD VESSEL INJURY; CARDIOMETABOLIC DISEASE; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; FATTY LIVER; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INSULIN RESISTANCE; METABOLIC DISORDER; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; CARDIOMEGALY; PATHOPHYSIOLOGY; PHYSIOLOGY;

CARDIOMEGALY; CARDIOVASCULAR DISEASES; FATTY LIVER; HUMANS; HYPERTENSION; INSULIN RESISTANCE; INTERFERON REGULATORY FACTORS; METABOLIC DISEASES; OBESITY; SIGNAL TRANSDUCTION;

EID: 84937574251     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.115.04898     Document Type: Review

References (277)

1. Daniel M, Lekkas P, Cargo M, Stankov I, Brown A., Environmental risk conditions and pathways to cardiometabolic diseases in indigenous populations. Annu Rev Public Health 2011;32:327-347. doi: 10.1146/annurev.publhealth.012809.103557
2. Mozaffarian D, Benjamin EJ, Go AS, American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics-2015 update: A report from the American Heart Association. Circulation 2015;131:e29-322. doi: 10.1161/CIR.0000000000000152
3. Hotamisligil GS., Inflammation and metabolic disorders. Nature 2006;444:860-867. doi: 10.1038/nature05485
4. Van Gaal LF, Mertens IL, De Block CE., Mechanisms linking obesity with cardiovascular disease. Nature 2006;444:875-880. doi: 10.1038/nature05487
5. Zhang XJ, Wang PX, Zhang P, Li H., Reply to: "Interferon regulatory factor 9 plays a dual function in health and disease". J Hepatol 2015;62:1447-1448. doi: 10.1016/j.jhep.2015.02.013
6. Dinarello CA., Anti-inflammatory Agents: Present and Future. Cell 2010;140:935-950. doi: 10.1016/j.cell.2010.02.043
7. Janeway CA Jr, Medzhitov R., Innate immune recognition. Annu Rev Immunol 2002;20:197-216. doi: 10.1146/annurev.immunol.20.083001.084359
8. Tamura T, Yanai H, Savitsky D, Taniguchi T., The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol 2008;26:535-584. doi: 10.1146/annurev.immunol.26.021607.090400
9. Zhao GN, Jiang DS, Li H., Interferon regulatory factors: At the crossroads of immunity, metabolism, and disease. Biochim Biophys Acta 2015;1852:365-378. doi: 10.1016/j.bbadis.2014.04.030
10. Zhang XJ, Jiang DS, Li H., Interferon regulatory factors as novel potential targets in the treatment of cardiovascular diseases. Br J Pharmacol 2014. doi: 10.1111/bph.12881
11. Savitsky D, Tamura T, Yanai H, Taniguchi T., Regulation of immunity and oncogenesis by the IRF transcription factor family. Cancer Immunol Immunother 2010;59:489-510. doi: 10.1007/s00262-009-0804-6
12. Honda K, Taniguchi T., IRFs: Master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 2006;6:644-658. doi: 10.1038/nri1900
13. Brass AL, Zhu AQ, Singh H., Assembly requirements of PU.1-Pip (IRF-4) activator complexes: Inhibiting function in vivo using fused dimers. EMBO J 1999;18:977-991. doi: 10.1093/emboj/18.4.977
14. Gupta S, Jiang M, Anthony A, Pernis AB., Lineage-specific modulation of interleukin 4 signaling by interferon regulatory factor 4. J Exp Med 1999;190:1837-1848.
15. Barnes BJ, Kellum MJ, Field AE, Pitha PM., Multiple regulatory domains of IRF-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes. Mol Cell Biol 2002;22:5721-5740.
16. Barnes BJ, Field AE, Pitha-Rowe PM., Virus-induced heterodimer formation between IRF-5 and IRF-7 modulates assembly of the IFNA enhanceosome in vivo and transcriptional activity of IFNA genes. J Biol Chem 2003;278:16630-16641. doi: 10.1074/jbc.M212609200
17. Lohoff M, Mak TW., Roles of interferon-regulatory factors in T-helper-cell differentiation. Nat Rev Immunol 2005;5:125-135. doi: 10.1038/nri1552
18. Harada H, Fujita T, Miyamoto M, Kimura Y, Maruyama M, Furia A, Miyata T, Taniguchi T., Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell 1989;58:729-739.
19. Reich NC., Nuclear/cytoplasmic localization of IRFs in response to viral infection or interferon stimulation. J Interferon Cytokine Res 2002;22:103-109. doi: 10.1089/107999002753452719
20. Kröger A, Köster M, Schroeder K, Hauser H, Mueller PP., Activities of IRF-1. J Interferon Cytokine Res 2002;22:5-14. doi: 10.1089/107999002753452610
21. Matsuyama T, Kimura T, Kitagawa M, Pfeffer K, Kawakami T, Watanabe N, Kündig TM, Amakawa R, Kishihara K, Wakeham A., Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development. Cell 1993;75:83-97.
22. Blanco JC, Contursi C, Salkowski CA, DeWitt DL, Ozato K, Vogel SN., Interferon regulatory factor (IRF)-1 and IRF-2 regulate interferon gamma-dependent cyclooxygenase 2 expression. J Exp Med 2000;191:2131-2144.
23. Mills KH., Induction, function and regulation of IL-17-producing T cells. Eur J Immunol 2008;38:2636-2649. doi: 10.1002/eji.200838535
24. Verthelyi D, Zeuner RA., Differential signaling by CpG DNA in DCs and B cells: Not just TLR9. Trends Immunol 2003;24:519-522.
25. Santana-de Anda K, Gomez-Martin D, Monsivais-Urenda AE, Salgado-Bustamante M, Gonzalez-Amaro R, Alcocer-Varela J., Interferon regulatory factor 3 as key element of the interferon signature in plasmacytoid dendritic cells from systemic lupus erythematosus patients: Novel genetic associations in the mexican mestizo population. Clin Exp Immunol 2014;178:428-437.
26. Kim KI, Malakhova OA, Hoebe K, Yan M, Beutler B, Zhang DE., Enhanced antibacterial potential in UBP43-deficient mice against Salmonella typhimurium infection by up-regulating type I IFN signaling. J Immunol 2005;175:847-854.
27. Sato M, Suemori H, Hata N, Asagiri M, Ogasawara K, Nakao K, Nakaya T, Katsuki M, Noguchi S, Tanaka N, Taniguchi T., Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction. Immunity 2000;13:539-548.
28. Huber M, Lohoff M., IRF4 at the crossroads of effector T-cell fate decision. Eur J Immunol 2014;44:1886-1895. doi: 10.1002/eji.201344279
29. Guo S, Li ZZ, Jiang DS, Lu YY, Liu Y, Gao L, Zhang SM, Lei H, Zhu LH, Zhang XD, Liu DP, Li H., IRF4 is a novel mediator for neuronal survival in ischaemic stroke. Cell Death Differ 2014;21:888-903. doi: 10.1038/cdd.2014.9
30. Lu R., Interferon regulatory factor 4 and 8 in B-cell development. Trends Immunol 2008;29:487-492. doi: 10.1016/j.it.2008.07.006
31. Lacey DC, Achuthan A, Fleetwood AJ, Dinh H, Roiniotis J, Scholz GM, Chang MW, Beckman SK, Cook AD, Hamilton JA., Defining GM-CSF- and macrophage-CSF-dependent macrophage responses by in vitro models. J Immunol 2012;188:5752-5765. doi: 10.4049/jimmunol.1103426
32. Ryzhakov G, Eames HL, Udalova IA., Activation and function of interferon regulatory factor 5. J Interferon Cytokine Res 2015;35:71-78. doi: 10.1089/jir.2014.0023
33. Fang CM, Roy S, Nielsen E, Paul M, Maul R, Paun A, Koentgen F, Raval FM, Szomolanyi-Tsuda E, Pitha PM., Unique contribution of IRF-5-Ikaros axis to the B-cell IgG2a response. Genes Immun 2012;13:421-430. doi: 10.1038/gene.2012.10
34. Xu WD, Pan HF, Xu Y, Ye DQ., Interferon regulatory factor 5 and autoimmune lupus. Expert Rev Mol Med 2013 15 e6. doi: 10.1017/erm.2013.7
35. Takaoka A, Yanai H, Kondo S, Duncan G, Negishi H, Mizutani T, Kano S, Honda K, Ohba Y, Mak TW, Taniguchi T., Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 2005;434:243-249. doi: 10.1038/nature03308
36. Ingraham CR, Kinoshita A, Kondo S, Yang B, Sajan S, Trout KJ, Malik MI, Dunnwald M, Goudy SL, Lovett M, Murray JC, Schutte BC., Abnormal skin, limb and craniofacial morphogenesis in mice deficient for interferon regulatory factor 6 (Irf6). Nat Genet 2006;38:1335-1340. doi: 10.1038/ng1903
37. Richardson RJ, Dixon J, Malhotra S, Hardman MJ, Knowles L, Boot-Handford RP, Shore P, Whitmarsh A, Dixon MJ., Irf6 is a key determinant of the keratinocyte proliferation-differentiation switch. Nat Genet 2006;38:1329-1334. doi: 10.1038/ng1894
38. Kondo S, Schutte BC, Richardson RJ, Mutations in IRF6 cause Van der Woude and popliteal pterygium syndromes. Nat Genet 2002;32:285-289. doi: 10.1038/ng985
39. Moretti F, Marinari B, Lo Iacono N, Botti E, Giunta A, Spallone G, Garaffo G, Vernersson-Lindahl E, Merlo G, Mills AA, Ballarò C, Alemà S, Chimenti S, Guerrini L, Costanzo A., A regulatory feedback loop involving p63 and IRF6 links the pathogenesis of 2 genetically different human ectodermal dysplasias. J Clin Invest 2010;120:1570-1577. doi: 10.1172/JCI40267
40. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, Shimada N, Ohba Y, Takaoka A, Yoshida N, Taniguchi T., IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005;434:772-777. doi: 10.1038/nature03464
41. Sato M, Hata N, Asagiri M, Nakaya T, Taniguchi T, Tanaka N., Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7. FEBS Lett 1998;441:106-110.
42. Zhang L, Pagano JS., Structure and function of IRF-7. J Interferon Cytokine Res 2002;22:95-101. doi: 10.1089/107999002753452700
43. Carmona FD, Gutala R, Simeón CP, Spanish Scleroderma Group Novel identification of the IRF7 region as an anticentromere autoantibody propensity locus in systemic sclerosis. Ann Rheum Dis 2012;71:114-119. doi: 10.1136/annrheumdis-2011-200275
44. Kanno Y, Levi BZ, Tamura T, Ozato K., Immune cell-specific amplification of interferon signaling by the IRF-4/8-PU.1 complex. J Interferon Cytokine Res 2005;25:770-779. doi: 10.1089/jir.2005.25.770
45. Tamura T, Ozato K., ICSBP/IRF-8: Its regulatory roles in the development of myeloid cells. J Interferon Cytokine Res 2002;22:145-152. doi: 10.1089/107999002753452755
46. Cattoretti G, Shaknovich R, Smith PM, Jäck HM, Murty VV, Alobeid B., Stages of germinal center transit are defined by B cell transcription factor coexpression and relative abundance. J Immunol 2006;177:6930-6939.
47. Ouyang X, Zhang R, Yang J, Transcription factor IRF8 directs a silencing programme for TH17 cell differentiation. Nat Commun 2011;2:314. doi: 10.1038/ncomms1311
48. Mattei F, Schiavoni G, Borghi P, Venditti M, Canini I, Sestili P, Pietraforte I, Morse HC III, Ramoni C, Belardelli F, Gabriele L., ICSBP/IRF-8 differentially regulates antigen uptake during dendritic-cell development and affects antigen presentation to CD4+ T cells. Blood 2006;108:609-617. doi: 10.1182/blood-2005-11-4490
49. Levy D, Darnell JE Jr, Interferon-dependent transcriptional activation: Signal transduction without second messenger involvement? New Biol 1990;2:923-928.
50. Fink K, Grandvaux N., STAT2 and IRF9: Beyond ISGF3. JAKSTAT 2013 2 e27521. doi: 10.4161/jkst.27521
51. Ikushima H, Negishi H, Taniguchi T., The IRF family transcription factors at the interface of innate and adaptive immune responses. Cold Spring Harb Symp Quant Biol 2013;78:105-116. doi: 10.1101/sqb.2013.78.020321
52. Kwa MQ, Nguyen T, Huynh J, Ramnath D, De Nardo D, Lam PY, Reynolds EC, Hamilton JA, Sweet MJ, Scholz GM., Interferon regulatory factor 6 differentially regulates Toll-like receptor 2-dependent chemokine gene expression in epithelial cells. J Biol Chem 2014;289:19758-19768. doi: 10.1074/jbc.M114.584540
53. Negishi H, Fujita Y, Yanai H, Sakaguchi S, Ouyang X, Shinohara M, Takayanagi H, Ohba Y, Taniguchi T, Honda K., Evidence for licensing of IFN-gamma-induced IFN regulatory factor 1 transcription factor by MyD88 in Toll-like receptor-dependent gene induction program. Proc Natl Acad Sci U S A 2006;103:15136-15141. doi: 10.1073/pnas.0607181103
54. Chen W, Lam SS, Srinath H, Jiang Z, Correia JJ, Schiffer CA, Fitzgerald KA, Lin K, Royer WE Jr, Insights into interferon regulatory factor activation from the crystal structure of dimeric IRF5. Nat Struct Mol Biol 2008;15:1213-1220. doi: 10.1038/nsmb.1496
55. Honda K, Yanai H, Mizutani T, Negishi H, Shimada N, Suzuki N, Ohba Y, Takaoka A, Yeh WC, Taniguchi T., Role of a transductional-transcriptional processor complex involving MyD88 and IRF-7 in Toll-like receptor signaling. Proc Natl Acad Sci U S A 2004;101:15416-15421. doi: 10.1073/pnas.0406933101
56. Hoshino K, Sugiyama T, Matsumoto M, Tanaka T, Saito M, Hemmi H, Ohara O, Akira S, Kaisho T., IκB kinase-alpha is critical for interferon-alpha production induced by Toll-like receptors 7 and 9. Nature 2006;440:949-953. doi: 10.1038/nature04641
57. Tsujimura H, Tamura T, Kong HJ, Nishiyama A, Ishii KJ, Klinman DM, Ozato K., Toll-like receptor 9 signaling activates NF-κB through IFN regulatory factor-8/IFN consensus sequence binding protein in dendritic cells. J Immunol 2004;172:6820-6827.
58. Zhao J, Kong HJ, Li H, Huang B, Yang M, Zhu C, Bogunovic M, Zheng F, Mayer L, Ozato K, Unkeless J, Xiong H., IRF-8/interferon (IFN) consensus sequence-binding protein is involved in Toll-like receptor (TLR) signaling and contributes to the cross-talk between TLR and IFN-gamma signaling pathways. J Biol Chem 2006;281:10073-10080. doi: 10.1074/jbc.M507788200
59. Negishi H, Ohba Y, Yanai H, Takaoka A, Honma K, Yui K, Matsuyama T, Taniguchi T, Honda K., Negative regulation of Toll-like-receptor signaling by IRF-4. Proc Natl Acad Sci U S A 2005;102:15989-15994. doi: 10.1073/pnas.0508327102
60. Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, Coyle AJ, Liao SM, Maniatis T., IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 2003;4:491-496. doi: 10.1038/ni921
61. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, Takeuchi O, Sugiyama M, Okabe M, Takeda K, Akira S., Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003;301:640-643. doi: 10.1126/science.1087262
62. Sakaguchi S, Negishi H, Asagiri M, Nakajima C, Mizutani T, Takaoka A, Honda K, Taniguchi T., Essential role of IRF-3 in lipopolysaccharide-induced interferon-beta gene expression and endotoxin shock. Biochem Biophys Res Commun 2003;306:860-866.
63. Huang J, Liu T, Xu LG, Chen D, Zhai Z, Shu HB., SIKE is an IKK epsilon/TBK1-associated suppressor of TLR3- and virus-triggered IRF-3 activation pathways. EMBO J 2005;24:4018-4028. doi: 10.1038/sj.emboj.7600863
64. Saitoh T, Yamamoto M, Miyagishi M, Taira K, Nakanishi M, Fujita T, Akira S, Yamamoto N, Yamaoka S., A20 is a negative regulator of IFN regulatory factor 3 signaling. J Immunol 2005;174:1507-1512.
65. He YW, Li H, Zhang J, Hsu CL, Lin E, Zhang N, Guo J, Forbush KA, Bevan MJ., The extracellular matrix protein mindin is a pattern-recognition molecule for microbial pathogens. Nat Immunol 2004;5:88-97. doi: 10.1038/ni1021
66. del Fresno C, Soulat D, Roth S, Blazek K, Udalova I, Sancho D, Ruland J, Ardavín C., Interferon-β production via Dectin-1-Syk-IRF5 signaling in dendritic cells is crucial for immunity to C. albicans. Immunity 2013;38:1176-1186. doi: 10.1016/j.immuni.2013.05.010
67. Wilkins C, Gale M Jr, Recognition of viruses by cytoplasmic sensors. Curr Opin Immunol 2010;22:41-47. doi: 10.1016/j.coi.2009.12.003
68. Sharma S, tenOever BR, Grandvaux N, Zhou GP, Lin R, Hiscott J., Triggering the interferon antiviral response through an IKK-related pathway. Science 2003;300:1148-1151. doi: 10.1126/science.1081315
69. Lin R, Yang L, Nakhaei P, Sun Q, Sharif-Askari E, Julkunen I, Hiscott J., Negative regulation of the retinoic acid-inducible gene I-induced antiviral state by the ubiquitin-editing protein A20. J Biol Chem 2006;281:2095-2103. doi: 10.1074/jbc.M510326200
70. Lazear HM, Lancaster A, Wilkins C, Suthar MS, Huang A, Vick SC, Clepper L, Thackray L, Brassil MM, Virgin HW, Nikolich-Zugich J, Moses A, Gale M Jr. M, Früh, Diamond MS., IRF-3, IRF-5, and IRF-7 coordinately regulate the type I IFN response in myeloid dendritic cells downstream of MAVS signaling. Plos Pathog 2013 9 1 e1003118. doi: 10.1371/journal.ppat.1003118
71. Sabbah A, Chang TH, Harnack R, Frohlich V, Tominaga K, Dube PH, Xiang Y, Bose S., Activation of innate immune antiviral responses by Nod2. Nat Immunol 2009;10:1073-1080. doi: 10.1038/ni.1782
72. Chang Foreman HC, Van Scoy S, Cheng TF, Reich NC., Activation of interferon regulatory factor 5 by site specific phosphorylation. PLoS One 2012 7 e33098. doi: 10.1371/journal.pone.0033098
73. Stetson DB, Medzhitov R., Recognition of cytosolic DNA activates an IRF3-dependent innate immune response. Immunity 2006;24:93-103. doi: 10.1016/j.immuni.2005.12.003
74. Taniguchi T, Ogasawara K, Takaoka A, Tanaka N., IRF family of transcription factors as regulators of host defense. Annu Rev Immunol 2001;19:623-655. doi: 10.1146/annurev.immunol.19.1.623
75. Sato M, Taniguchi T, Tanaka N., The interferon system and interferon regulatory factor transcription factors-studies from gene knockout mice. Cytokine Growth Factor Rev 2001;12:133-142.
76. Zimmermann A, Trilling M, Wagner M, Wilborn M, Bubic I, Jonjic S, Koszinowski U, Hengel H., A cytomegaloviral protein reveals a dual role for STAT2 in IFN-γ signaling and antiviral responses. J Exp Med 2005;201:1543-1553. doi: 10.1084/jem.20041401
77. Versteeg GA, Benke S, García-Sastre A, Rajsbaum R., InTRIMsic immunity: Positive and negative regulation of immune signaling by tripartite motif proteins. Cytokine Growth Factor Rev 2014;25:563-576. doi: 10.1016/j.cytogfr.2014.08.001
78. Nakazawa T, Satoh J, Takahashi K, Complete suppression of insulitis and diabetes in NOD mice lacking interferon regulatory factor-1. J Autoimmun 2001;17:119-125. doi: 10.1006/jaut.2001.0531
79. Jiang DS, Li L, Huang L, Gong J, Xia H, Liu X, Wan N, Wei X, Zhu X, Chen Y, Chen X, Zhang XD, Li H., Interferon regulatory factor 1 is required for cardiac remodeling in response to pressure overload. Hypertension 2014;64:77-86. doi: 10.1161/HYPERTENSIONAHA.114.03229
80. Alexander M, Forster C, Sugimoto K, Clark HB, Vogel S, Ross ME, Iadecola C., Interferon regulatory factor-1 immunoreactivity in neurons and inflammatory cells following ischemic stroke in rodents and humans. Acta Neuropathol 2003;105:420-424. doi: 10.1007/s00401-002-0658-x
81. Tsung A, Stang MT, Ikeda A, Critchlow ND, Izuishi K, Nakao A, Chan MH, Jeyabalan G, Yim JH, Geller DA., The transcription factor interferon regulatory factor-1 mediates liver damage during ischemia-reperfusion injury. Am J Physiol Gastrointest Liver Physiol 2006 290 G1261 G1268. doi: 10.1152/ajpgi.00460.2005
82. Miyamoto M, Fujita T, Kimura Y, Maruyama M, Harada H, Sudo Y, Miyata T, Taniguchi T., Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-beta gene regulatory elements. Cell 1988;54:903-913.
83. Klune JR, Dhupar R, Kimura S, Ueki S, Cardinal J, Nakao A, Nace G, Evankovich J, Murase N, Tsung A, Geller DA., Interferon regulatory factor-2 is protective against hepatic ischemia-reperfusion injury. Am J Physiol Gastrointest Liver Physiol 2012 303 G666 G673. doi: 10.1152/ajpgi.00050.2012
84. Zhang SM, Zhu LH, Li ZZ, Wang PX, Chen HZ, Guan HJ, Jiang DS, Chen K, Zhang XF, Tian S, Yang D, Zhang XD, Li H., Interferon regulatory factor 3 protects against adverse neo-intima formation. Cardiovasc Res 2014;102:469-479. doi: 10.1093/cvr/cvu052
85. Bauer EM, Shapiro R, Billiar TR, Bauer PM., High mobility group Box 1 inhibits human pulmonary artery endothelial cell migration via a Toll-like receptor 4- and interferon response factor 3-dependent mechanism(s). J Biol Chem 2013;288:1365-1373. doi: 10.1074/jbc.M112.434142
86. Loi P, Yuan Q, Torres D, Delbauve S, Laute MA, Lalmand MC, Pétein M, Goriely S, Goldman M, Flamand V., Interferon regulatory factor 3 deficiency leads to interleukin-17-mediated liver ischemia-reperfusion injury. Hepatology 2013;57:351-361. doi: 10.1002/hep.26022
87. Au WC, Moore PA, Lowther W, Juang YT, Pitha PM., Identification of a member of the interferon regulatory factor family that binds to the interferon-stimulated response element and activates expression of interferon-induced genes. Proc Natl Acad Sci U S A 1995;92:11657-11661.
88. Eguchi J, Kong X, Tenta M, Wang X, Kang S, Rosen ED., Interferon regulatory factor 4 regulates obesity-induced inflammation through regulation of adipose tissue macrophage polarization. Diabetes 2013;62:3394-3403. doi: 10.2337/db12-1327
89. Kong X, Banks A, Liu T, IRF4 is a key thermogenic transcriptional partner of PGC-1α. Cell 2014;158:69-83. doi: 10.1016/j.cell.2014.04.049
90. Lenna S, Farina AG, Martyanov V, Christmann RB, Wood TA, Farber HW, Scorza R, Whitfield ML, Lafyatis R, Trojanowska M., Increased expression of endoplasmic reticulum stress and unfolded protein response genes in peripheral blood mononuclear cells from patients with limited cutaneous systemic sclerosis and pulmonary arterial hypertension. Arthritis Rheum 2013;65:1357-1366. doi: 10.1002/art.37891
91. Jiang DS, Bian ZY, Zhang Y, Zhang SM, Liu Y, Zhang R, Chen Y, Yang Q, Zhang XD, Fan GC, Li H., Role of interferon regulatory factor 4 in the regulation of pathological cardiac hypertrophy. Hypertension 2013;61:1193-1202. doi: 10.1161/HYPERTENSIONAHA.111.00614
92. Xu H, Krolikowski JG, Jones DW, Ge ZD, Pagel PS, Pritchard KA Jr, Weihrauch D., 4F decreases IRF5 expression and activation in hearts of tight skin mice. PLoS One 2012 7 e52046. doi: 10.1371/journal.pone.0052046
93. Courties G, Heidt T, Sebas M, In vivo silencing of the transcription factor IRF5 reprograms the macrophage phenotype and improves infarct healing. J Am Coll Cardiol 2014;63:1556-1566. doi: 10.1016/j.jacc.2013.11.023
94. Barnes BJ, Moore PA, Pitha PM., Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes. J Biol Chem 2001;276:23382-23390. doi: 10.1074/jbc.M101216200
95. Wang XA, Zhang R, Zhang S, Deng S, Jiang D, Zhong J, Yang L, Wang T, Hong S, Guo S, She ZG, Zhang XD, Li H., Interferon regulatory factor 7 deficiency prevents diet-induced obesity and insulin resistance. Am J Physiol Endocrinol Metab 2013 305 E485 E495. doi: 10.1152/ajpendo.00505.2012
96. Huang L, Zhang SM, Zhang P, Zhang XJ, Zhu LH, Chen K, Gao L, Zhang Y, Kong XJ, Tian S, Zhang XD, Li H., Interferon regulatory factor 7 protects against vascular smooth muscle cell proliferation and neointima formation. J Am Heart Assoc 2014 3 e001309. doi: 10.1161/JAHA.114.001309
97. Jiang DS, Liu Y, Zhou H, Interferon regulatory factor 7 functions as a novel negative regulator of pathological cardiac hypertrophy. Hypertension 2014;63:713-722. doi: 10.1161/HYPERTENSIONAHA.113.02653
98. Leung PY, Stevens SL, Packard AE, Lessov NS, Yang T, Conrad VK, van den Dungen NN, Simon RP, Stenzel-Poore MP., Toll-like receptor 7 preconditioning induces robust neuroprotection against stroke by a novel type I interferon-mediated mechanism. Stroke 2012;43:1383-1389. doi: 10.1161/STROKEAHA.111.641522
99. Zhang L, Pagano JS., IRF-7, a new interferon regulatory factor associated with Epstein-Barr virus latency. Mol Cell Biol 1997;17:5748-5757.
100. Zhang SM, Gao L, Zhang XF, Zhang R, Zhu LH, Wang PX, Tian S, Yang D, Chen K, Huang L, Zhang XD, Li H., Interferon regulatory factor 8 modulates phenotypic switching of smooth muscle cells by regulating the activity of myocardin. Mol Cell Biol 2014;34:400-414. doi: 10.1128/MCB.01070-13
101. Jiang DS, Wei X, Zhang XF, IRF8 suppresses pathological cardiac remodelling by inhibiting calcineurin signalling. Nat Commun 2014;5:3303. doi: 10.1038/ncomms4303
102. Xiang M, Wang L, Guo S, Lu YY, Lei H, Jiang DS, Zhang Y, Liu Y, Zhou Y, Zhang XD, Li H., Interferon regulatory factor 8 protects against cerebral ischaemic-reperfusion injury. J Neurochem 2014;129:988-1001. doi: 10.1111/jnc.12682
103. Wang XA, Zhang R, Jiang D, Interferon regulatory factor 9 protects against hepatic insulin resistance and steatosis in male mice. Hepatology 2013;58:603-616. doi: 10.1002/hep.26368
104. Zhang SM, Zhu LH, Chen HZ, Zhang R, Zhang P, Jiang DS, Gao L, Tian S, Wang L, Zhang Y, Wang PX, Zhang XF, Zhang XD, Liu DP, Li H., Interferon regulatory factor 9 is critical for neointima formation following vascular injury. Nat Commun 2014;5:5160. doi: 10.1038/ncomms6160
105. Jiang DS, Luo YX, Zhang R, Zhang XD, Chen HZ, Zhang Y, Chen K, Zhang SM, Fan GC, Liu PP, Liu DP, Li H., Interferon regulatory factor 9 protects against cardiac hypertrophy by targeting myocardin. Hypertension 2014;63:119-127. doi: 10.1161/HYPERTENSIONAHA.113.02083
106. Deng W, Wang X, Xiao J, Chen K, Zhou H, Shen D, Li H, Tang Q., Loss of regulator of G protein signaling 5 exacerbates obesity, hepatic steatosis, inflammation and insulin resistance. PLoS One 2012 7 e30256. doi: 10.1371/journal.pone.0030256
107. Postic C, Girard J., Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: Lessons from genetically engineered mice. J Clin Invest 2008;118:829-838. doi: 10.1172/JCI34275
108. Lee CH, Olson P, Evans RM., Minireview: Lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003;144:2201-2207. doi: 10.1210/en.2003-0288
109. Fabbrini E, Sullivan S, Klein S., Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications. Hepatology 2010;51:679-689. doi: 10.1002/hep.23280
110. Minnich A, Tian N, Byan L, Bilder G., A potent PPARalpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle. Am J Physiol Endocrinol Metab 2001 280 E270 E279
111. Fu Y, Luo N, Klein RL, Garvey WT., Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. J Lipid Res 2005;46:1369-1379. doi: 10.1194/jlr.M400373-JLR200
112. Leibowitz MD, Fiévet C, Hennuyer N, Activation of PPARdelta alters lipid metabolism in db/db mice. FEBS Lett 2000;473:333-336.
113. Baker RG, Hayden MS, Ghosh S., NF-κB, inflammation, and metabolic disease. Cell Metab 2011;13:11-22. doi: 10.1016/j.cmet.2010.12.008
114. Steinberg GR, Kemp BE., AMPK in Health and Disease. Physiol Rev 2009;89:1025-1078. doi: 10.1152/physrev.00011.2008
115. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, Tuncman G, Görgün C, Glimcher LH, Hotamisligil GS., Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004;306:457-461. doi: 10.1126/science.1103160
116. Eguchi J, Yan QW, Schones DE, Kamal M, Hsu CH, Zhang MQ, Crawford GE, Rosen ED., Interferon regulatory factors are transcriptional regulators of adipogenesis. Cell Metab 2008;7:86-94. doi: 10.1016/j.cmet.2007.11.002
117. Wang XA, Zhang R, She ZG, Zhang XF, Jiang DS, Wang T, Gao L, Deng W, Zhang SM, Zhu LH, Guo S, Chen K, Zhang XD, Liu DP, Li H., Interferon regulatory factor 3 constrains IKKβ/NF-κB signaling to alleviate hepatic steatosis and insulin resistance. Hepatology 2014;59:870-885. doi: 10.1002/hep.26751
118. Tang P, Zhang Y., Regulatory function of interferon regulatory factor 3 in obesity, inflammation and insulin resistance. J Immunol 2014;192.
119. Kim S, Jin Y, Choi Y, Park T., Resveratrol exerts anti-obesity effects via mechanisms involving down-regulation of adipogenic and inflammatory processes in mice. Biochem Pharmacol 2011;81:1343-1351. doi: 10.1016/j.bcp.2011.03.012
120. Fabrizi M, Marchetti V, Mavilio M, IL-21 is a major negative regulator of IRF4-dependent lipolysis affecting Tregs in adipose tissue and systemic insulin sensitivity. Diabetes 2014;63:2086-2096. doi: 10.2337/db13-0939
121. Knudsen NH, Lee CH., IL-21 and IRF4: A complex partnership in immune and metabolic regulation. Diabetes 2014;63:1838-1840. doi: 10.2337/db14-0273
122. Dalmas E, Toubal A, Alzaid F, Blazek K, Eames HL, Lebozec K, Pini M, Hainault I, Montastier E, Denis RG, Ancel P, Lacombe A, Ling Y, Allatif O, Cruciani-Guglielmacci C, Andre S, Viguerie N, Poitou C, Stich V, Torcivia A, Foufelle F, Luquet S, Aron-Wisnewsky J, Langin D, Clement K, Udalova IA, Venteclef N., Irf5 deficiency in macrophages promotes beneficial adipose tissue expansion and insulin sensitivity during obesity. Nat Med 2015. doi: 10.1038/nm.3829
123. Kraus TA, Lau JF, Parisien JP, Horvath CM., A hybrid IRF9-STAT2 protein recapitulates interferon-stimulated gene expression and antiviral response. J Biol Chem 2003;278:13033-13038. doi: 10.1074/jbc.M212972200
124. Dzau VJ, Braun-Dullaeus RC, Sedding DG., Vascular proliferation and atherosclerosis: New perspectives and therapeutic strategies. Nat Med 2002;8:1249-1256. doi: 10.1038/nm1102-1249
125. She ZG, Zheng W, Wei YS, Chen HZ, Wang AB, Li HL, Liu G, Zhang R, Liu JJ, Stallcup WB, Zhou Z, Liu DP, Liang CC., Human paraoxonase gene cluster transgenic overexpression represses atherogenesis and promotes atherosclerotic plaque stability in ApoE-null mice. Circ Res 2009;104:1160-1168. doi: 10.1161/CIRCRESAHA.108.192229
126. Khurana R, Zhuang Z, Bhardwaj S, Murakami M, De Muinck E, Yla-Herttuala S, Ferrara N, Martin JF, Zachary I, Simons M., Angiogenesis-dependent and independent phases of intimal hyperplasia. Circulation 2004;110:2436-2443. doi: 10.1161/01.CIR.0000145138.25577.F1
127. Zhu LH, Wang L, Wang D, Jiang H, Tang QZ, Yan L, Bian ZY, Wang XA, Li H., Puerarin attenuates high-glucose-and diabetes-induced vascular smooth muscle cell proliferation by blocking PKCbeta2/Rac1-dependent signaling. Free Radic Biol Med 2010;48:471-482. doi: 10.1016/j.freeradbiomed.2009.10.040
128. Davis-Dusenbery BN, Wu C, Hata A., Micromanaging vascular smooth muscle cell differentiation and phenotypic modulation. Arterioscler Thromb Vasc Biol 2011;31:2370-2377. doi: 10.1161/ATVBAHA.111.226670
129. Newby AC., Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 2005;85:1-31. doi: 10.1152/physrev.00048.2003
130. Inoue T, Croce K, Morooka T, Sakuma M, Node K, Simon DI., Vascular inflammation and repair: Implications for re-endothelialization, restenosis, and stent thrombosis. JACC Cardiovasc Interv 2011;4:1057-1066. doi: 10.1016/j.jcin.2011.05.025
131. Alexander MR, Owens GK., Epigenetic control of smooth muscle cell differentiation and phenotypic switching in vascular development and disease. Annu Rev Physiol 2012;74:13-40. doi: 10.1146/annurev-physiol-012110-142315
132. Hayashi S, Watanabe N, Nakazawa K, Suzuki J, Tsushima K, Tamatani T, Sakamoto S, Isobe M., Roles of P-selectin in inflammation, neointimal formation, and vascular remodeling in balloon-injured rat carotid arteries. Circulation 2000;102:1710-1717.
133. Dimayuga PC, Li H, Chyu KY, Fredrikson GN, Nilsson J, Fishbein MC, Shah PK, Cercek B., T cell modulation of intimal thickening after vascular injury: The bimodal role of IFN-gamma in immune deficiency. Arterioscler Thromb Vasc Biol 2005;25:2528-2534. doi: 10.1161/01.ATV.0000190606.41121.00
134. Wang Y, Bai Y, Qin L, Zhang P, Yi T, Teesdale SA, Zhao L, Pober JS, Tellides G., Interferon-gamma induces human vascular smooth muscle cell proliferation and intimal expansion by phosphatidylinositol 3-kinase dependent mammalian target of rapamycin raptor complex 1 activation. Circ Res 2007;101:560-569. doi: 10.1161/CIRCRESAHA.107.151068
135. Kusaba K, Kai H, Koga M, Takayama N, Ikeda A, Yasukawa H, Seki Y, Egashira K, Imaizumi T., Inhibition of intrinsic interferon-gamma function prevents neointima formation after balloon injury. Hypertension 2007;49:909-915. doi: 10.1161/01.HYP.0000259668.37901.8c
136. Li Z, Wang ZG, Bian C, Chen XD, Li JW, Chen X, Han B, Hou GF, Chu J, Cui Q., Interferon regulatory factor-1 exerts inhibitory effect on neointimal formation after vascular injury. Chin Med Sci J 2009;24:91-96.
137. Wessely R, Hengst L, Jaschke B, Wegener F, Richter T, Lupetti R, Paschalidis M, Schömig A, Brandl R, Neumann FJ., A central role of interferon regulatory factor-1 for the limitation of neointimal hyperplasia. Hum Mol Genet 2003;12:177-187.
138. Harats D, Yacov N, Gilburd B, Shoenfeld Y, George J., Oral tolerance with heat shock protein 65 attenuates Mycobacterium tuberculosis-induced and high-fat-diet-driven atherosclerotic lesions. J Am Coll Cardiol 2002;40:1333-1338.
139. Sun C, Alkhoury K, Wang YI, Foster GA, Radecke CE, Tam K, Edwards CM, Facciotti MT, Armstrong EJ, Knowlton AA, Newman JW, Passerini AG, Simon SI., IRF-1 and miRNA126 modulate VCAM-1 expression in response to a high-fat meal. Circ Res 2012;111:1054-1064. doi: 10.1161/CIRCRESAHA.112.270314
140. Marmur JD, Poon M, Rossikhina M, Taubman MB., Induction of PDGF-responsive genes in vascular smooth muscle. Implications for the early response to vessel injury. Circulation 1992;86:III53-III60.
141. Kuvin JT, Karas RH., Clinical utility of endothelial function testing: Ready for prime time? Circulation 2003;107:3243-3247. doi: 10.1161/01.CIR.0000075928.54461.33
142. Patel SJ, Jindal R, King KR, Tilles AW, Yarmush ML., The inflammatory response to double stranded DNA in endothelial cells is mediated by NFκB and TNFα. PLoS One 2011 6 e19910. doi: 10.1371/journal.pone.0019910
143. Holland JW, Bird S, Williamson B, Woudstra C, Mustafa A, Wang T, Zou J, Blaney SC, Collet B, Secombes CJ., Molecular characterization of IRF3 and IRF7 in rainbow trout, Oncorhynchus mykiss: Functional analysis and transcriptional modulation. Mol Immunol 2008;46:269-285. doi: 10.1016/j.molimm.2008.08.265
144. Lehtonen A, Lund R, Lahesmaa R, Julkunen I, Sareneva T, Matikainen S., IFN-alpha and IL-12 activate IFN regulatory factor 1 (IRF-1), IRF-4, and IRF-8 gene expression in human NK and T cells. Cytokine 2003;24:81-90.
145. Döring Y, Soehnlein O, Drechsler M, Shagdarsuren E, Chaudhari SM, Meiler S, Hartwig H, Hristov M, Koenen RR, Hieronymus T, Zenke M, Weber C, Zernecke A., Hematopoietic interferon regulatory factor 8-deficiency accelerates atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2012;32:1613-1623. doi: 10.1161/ATVBAHA.111.236539
146. Yoshida T, Sinha S, Dandré F, Wamhoff BR, Hoofnagle MH, Kremer BE, Wang DZ, Olson EN, Owens GK., Myocardin is a key regulator of CArG-dependent transcription of multiple smooth muscle marker genes. Circ Res 2003;92:856-864. doi: 10.1161/01.RES.0000068405.49081.09
147. Li L, Zhang HN, Chen HZ, SIRT1 acts as a modulator of neointima formation following vascular injury in mice. Circ Res 2011;108:1180-1189. doi: 10.1161/CIRCRESAHA.110.237875
148. Longo GM, Xiong W, Greiner TC, Zhao Y, Fiotti N, Baxter BT., Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 2002;110:625-632. doi: 10.1172/JCI15334
149. Heineke J, Molkentin JD., Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006;7:589-600. doi: 10.1038/nrm1983
150. Li H, He C, Feng J, Zhang Y, Tang Q, Bian Z, Bai X, Zhou H, Jiang H, Heximer SP, Qin M, Huang H, Liu PP, Huang C., Regulator of G protein signaling 5 protects against cardiac hypertrophy and fibrosis during biomechanical stress of pressure overload. Proc Natl Acad Sci U S A 2010;107:13818-13823. doi: 10.1073/pnas.1008397107
151. Li H, Tang QZ, Liu C, Moon M, Chen M, Yan L, Bian ZY, Zhang Y, Wang AB, Nghiem MP, Liu PP., Cellular FLICE-inhibitory protein protects against cardiac remodeling induced by angiotensin II in mice. Hypertension 2010;56:1109-1117. doi: 10.1161/HYPERTENSIONAHA.110.157412
152. Sutton MG, Sharpe N., Left ventricular remodeling after myocardial infarction: Pathophysiology and therapy. Circulation 2000;101:2981-2988.
153. Bertorello AM, Pires N, Igreja B, Pinho MJ, Vorkapic E, Wågsäter D, Wikström J, Behrendt M, Hamsten A, Eriksson P, Soares-da-Silva P, Brion L., Increased arterial blood pressure and vascular remodeling in mice lacking salt-inducible kinase 1 (SIK1). Circ Res 2015;116:642-652. doi: 10.1161/CIRCRESAHA.116.304529
154. Li HL, She ZG, Li TB, Wang AB, Yang Q, Wei YS, Wang YG, Liu DP., Overexpression of myofibrillogenesis regulator-1 aggravates cardiac hypertrophy induced by angiotensin II in mice. Hypertension 2007;49:1399-1408. doi: 10.1161/HYPERTENSIONAHA.106.085399
155. Bian ZY, Huang H, Jiang H, Shen DF, Yan L, Zhu LH, Wang L, Cao F, Liu C, Tang QZ, Li H., LIM and cysteine-rich domains 1 regulates cardiac hypertrophy by targeting calcineurin/nuclear factor of activated T cells signaling. Hypertension 2010;55:257-263. doi: 10.1161/HYPERTENSIONAHA.109.135665
156. Zhang Y, Liu Y, Zhu XH, Dickkopf-3 attenuates pressure overload-induced cardiac remodelling. Cardiovasc Res 2014;102:35-45. doi: 10.1093/cvr/cvu004
157. Chen K, Gao L, Liu Y, Zhang Y, Jiang DS, Wei X, Zhu XH, Zhang R, Chen Y, Yang Q, Kioka N, Zhang XD, Li H., Vinexin-β protects against cardiac hypertrophy by blocking the Akt-dependent signalling pathway. Basic Res Cardiol 2013;108:338. doi: 10.1007/s00395-013-0338-0
158. Li S, Zhu J, Zhang W, Signature microRNA expression profile of essential hypertension and its novel link to human cytomegalovirus infection. Circulation 2011;124:175-184. doi: 10.1161/CIRCULATIONAHA.110.012237
159. Weber KT, Brilla CG., Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;83:1849-1865.
160. Tsushima K, Osawa T, Yanai H, Nakajima A, Takaoka A, Manabe I, Ohba Y, Imai Y, Taniguchi T, Nagai R., IRF3 regulates cardiac fibrosis but not hypertrophy in mice during angiotensin II-induced hypertension. FASEB J 2011;25:1531-1543. doi: 10.1096/fj.10-174615
161. Lu J, Bian ZY, Zhang R, Interferon regulatory factor 3 is a negative regulator of pathological cardiac hypertrophy. Basic Res Cardiol 2013;108:326. doi: 10.1007/s00395-012-0326-9
162. Gusterson RJ, Jazrawi E, Adcock IM, Latchman DS., The transcriptional co-activators CREB-binding protein (CBP) and p300 play a critical role in cardiac hypertrophy that is dependent on their histone acetyltransferase activity. J Biol Chem 2003;278:6838-6847. doi: 10.1074/jbc.M211762200
163. Weihrauch D, Xu H, Shi Y, Wang J, Brien J, Jones DW, Kaul S, Komorowski RA, Csuka ME, Oldham KT, Pritchard KA., Effects of D-4F on vasodilation, oxidative stress, angiostatin, myocardial inflammation, and angiogenic potential in tight-skin mice. Am J Physiol Heart Circ Physiol 2007;293:H1432-H1441. doi: 10.1152/ajpheart.00038.2007
164. Freund C, Schmidt-Ullrich R, Baurand A, Dunger S, Schneider W, Loser P, El-Jamali A, Dietz R, Scheidereit C, Bergmann MW., Requirement of nuclear factor-κB in angiotensin II- and isoproterenol-induced cardiac hypertrophy in vivo. Circulation 2005;111:2319-2325. doi: 10.1161/01.CIR.0000164237.58200.5A.
165. Hikoso S, Yamaguchi O, Nakano Y, The IκB kinase β/nuclear factor κB signaling pathway protects the heart from hemodynamic stress mediated by the regulation of manganese superoxide dismutase expression. Circ Res 2009;105:70-79. doi: 10.1161/CIRCRESAHA.108.193318
166. Baines CP., The mitochondrial permeability transition pore and ischemia-reperfusion injury. Basic Res Cardiol 2009;104:181-188. doi: 10.1007/s00395-009-0004-8
167. Collard CD, Gelman S., Pathophysiology, clinical manifestations, and prevention of ischemia-reperfusion injury. Anesthesiology 2001;94:1133-1138.
168. Xiao J, Moon M, Yan L, Nian M, Zhang Y, Liu C, Lu J, Guan H, Chen M, Jiang D, Jiang H, Liu PP, Li H., Cellular FLICE-inhibitory protein protects against cardiac remodelling after myocardial infarction. Basic Res Cardiol 2012;107:239. doi: 10.1007/s00395-011-0239-z
169. Murphy E, Steenbergen C., Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev 2008;88:581-609. doi: 10.1152/physrev.00024.2007
170. Paschen W, Gissel C, Althausen S, Doutheil J., Changes in interferon-regulatory factor-1 mRNA levels after transient ischemia in rat brain. Neuroreport 1998;9:3147-3151.
171. Iadecola C, Salkowski CA, Zhang F, Aber T, Nagayama M, Vogel SN, Ross ME., The transcription factor interferon regulatory factor 1 is expressed after cerebral ischemia and contributes to ischemic brain injury. J Exp Med 1999;189:719-727.
172. Castellaneta A, Yoshida O, Kimura S, Yokota S, Geller DA, Murase N, Thomson AW., Plasmacytoid dendritic cell-derived IFN-α promotes murine liver ischemia/reperfusion injury by induction of hepatocyte IRF-1. Hepatology 2014;60:267-277. doi: 10.1002/hep.27037
173. Kim KH, Dhupar R, Ueki S, Cardinal J, Pan P, Cao Z, Cho SW, Murase N, Tsung A, Geller DA., Donor graft interferon regulatory factor-1 gene transfer worsens liver transplant ischemia/reperfusion injury. Surgery 2009;146:181-189. doi: 10.1016/j.surg.2009.06.011
174. Ueki S, Dhupar R, Cardinal J, Tsung A, Yoshida J, Ozaki KS, Klune JR, Murase N, Geller DA., Critical role of interferon regulatory factor-1 in murine liver transplant ischemia reperfusion injury. Hepatology 2010;51:1692-1701. doi: 10.1002/hep.23501
175. Hida S, Ogasawara K, Sato K, Abe M, Takayanagi H, Yokochi T, Sato T, Hirose S, Shirai T, Taki S, Taniguchi T., CD8(+) T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-alpha/beta signaling. Immunity 2000;13:643-655.
176. Cui G, Ye X, Zuo T, Zhao H, Zhao Q, Chen W, Hua F., Chloroquine pretreatment inhibits toll-like receptor 3 signaling after stroke. Neurosci Lett 2013;548:101-104. doi: 10.1016/j.neulet.2013.02.072
177. Stevens SL, Leung PY, Vartanian KB, Gopalan B, Yang T, Simon RP, Stenzel-Poore MP., Multiple preconditioning paradigms converge on interferon regulatory factor-dependent signaling to promote tolerance to ischemic brain injury. J Neurosci 2011;31:8456-8463. doi: 10.1523/JNEUROSCI.0821-11.2011
178. Marsh B, Stevens SL, Packard AE, Gopalan B, Hunter B, Leung PY, Harrington CA, Stenzel-Poore MP., Systemic lipopolysaccharide protects the brain from ischemic injury by reprogramming the response of the brain to stroke: A critical role for IRF3. J Neurosci 2009;29:9839-9849. doi: 10.1523/JNEUROSCI.2496-09.2009
179. Panizzi P, Swirski FK, Figueiredo JL, Waterman P, Sosnovik DE, Aikawa E, Libby P, Pittet M, Weissleder R, Nahrendorf M., Impaired infarct healing in atherosclerotic mice with Ly-6C(hi) monocytosis. J Am Coll Cardiol 2010;55:1629-1638. doi: 10.1016/j.jacc.2009.08.089
180. Zhang Y, Liu X, She ZG, Jiang DS, Wan N, Xia H, Zhu XH, Wei X, Zhang XD, Li H., Interferon regulatory factor 9 is an essential mediator of heart dysfunction and cell death following myocardial ischemia/reperfusion injury. Basic Res Cardiol 2014;109:434. doi: 10.1007/s00395-014-0434-9
181. Chen HZ, Guo S, Li ZZ, A critical role for interferon regulatory factor 9 in cerebral ischemic stroke. J Neurosci 2014;34:11897-11912. doi: 10.1523/JNEUROSCI.1545-14.2014
182. Wang PX, Zhang R, Huang L, Zhu LH, Jiang DS, Chen HZ, Zhang Y, Tian S, Zhang XF, Zhang XD, Liu DP, Li H., Interferon regulatory factor 9 is a key mediator of hepatic ischemia/reperfusion injury. J Hepatol 2015;62:111-120. doi: 10.1016/j.jhep.2014.08.022
183. Chen WY, Wang DH, Yen RC, Luo J, Gu W, Baylin SB., Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 2005;123:437-448. doi: 10.1016/j.cell.2005.08.011
184. Beutler B., Inferences, questions and possibilities in Toll-like receptor signalling. Nature 2004;430:257-263. doi: 10.1038/nature02761
185. Seki E, Brenner DA., Toll-like receptors and adaptor molecules in liver disease: Update. Hepatology 2008;48:322-335. doi: 10.1002/hep.22306
186. Yu L, Wang L, Chen S., Endogenous toll-like receptor ligands and their biological significance. J Cell Mol Med 2010;14:2592-2603. doi: 10.1111/j.1582-4934.2010.01127.x
187. Balogh S, Kiss I, Csaszar A., Toll-like receptors: Link between "danger" ligands and plaque instability. Curr Drug Targets 2009;10:513-518.
188. Prajapati B, Jena PK, Rajput P, Purandhar K, Seshadri S., Understanding and modulating the Toll like Receptors (TLRs) and NOD like Receptors (NLRs) cross talk in type 2 diabetes. Curr Diabetes Rev 2014;10:190-200.
189. Miura K, Ohnishi H., Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World J Gastroenterol 2014;20:7381-7391. doi: 10.3748/wjg.v20.i23.7381
190. Kim SJ, Choi Y, Choi YH, Park T., Obesity activates toll-like receptor-mediated proinflammatory signaling cascades in the adipose tissue of mice. J Nutr Biochem 2012;23:113-122. doi: 10.1016/j.jnutbio.2010.10.012
191. Ehses JA, Meier DT, Wueest S, Toll-like receptor 2-deficient mice are protected from insulin resistance and beta cell dysfunction induced by a high-fat diet. Diabetologia 2010;53:1795-1806. doi: 10.1007/s00125-010-1747-3
192. Himes RW, Smith CW., Tlr2 is critical for diet-induced metabolic syndrome in a murine model. FASEB J 2010;24:731-739. doi: 10.1096/fj.09-141929
193. Fresno M, Alvarez R, Cuesta N., Toll-like receptors, inflammation, metabolism and obesity. Arch Physiol Biochem 2011;117:151-164. doi: 10.3109/13813455.2011.562514
194. Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M., Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol 2007;47:571-579. doi: 10.1016/j.jhep.2007.04.019
195. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS., TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006;116:3015-3025. doi: 10.1172/JCI28898
196. Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, Srinivasan S, Sitaraman SV, Knight R, Ley RE, Gewirtz AT., Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010;328:228-231. doi: 10.1126/science.1179721
197. Wang Z, Zheng Y, Hou C, Yang L, Li X, Lin J, Huang G, Lu Q, Wang CY, Zhou Z., DNA methylation impairs TLR9 induced Foxp3 expression by attenuating IRF-7 binding activity in fulminant type 1 diabetes. J Autoimmun 2013;41:50-59. doi: 10.1016/j.jaut.2013.01.009
198. Moynagh PN., TLR signalling and activation of IRFs: Revisiting old friends from the NF-κB pathway. Trends Immunol 2005;26:469-476. doi: 10.1016/j.it.2005.06.009
199. Chen Z, Sheng L, Shen H, Zhao Y, Wang S, Brink R, Rui L., Hepatic TRAF2 regulates glucose metabolism through enhancing glucagon responses. Diabetes 2012;61:566-573. doi: 10.2337/db11-0474
200. Chen Z, Shen H, Sun C, Yin L, Tang F, Zheng P, Liu Y, Brink R, Rui L., Myeloid cell TRAF3 promotes metabolic inflammation, insulin resistance, and hepatic steatosis in obesity. Am J Physiol Endocrinol Metab 2015 308 E460 E469. doi: 10.1152/ajpendo.00470.2014
201. Catrysse L, Vereecke L, Beyaert R, van Loo G., A20 in inflammation and autoimmunity. Trends Immunol 2014;35:22-31. doi: 10.1016/j.it.2013.10.005
202. Tailor P, Tamura T, Ozato K., IRF family proteins and type I interferon induction in dendritic cells. Cell Res 2006;16:134-140. doi: 10.1038/sj.cr.7310018
203. Hand LE, Usan P, Cooper GJ, Xu LY, Ammori B, Cunningham PS, Aghamohammadzadeh R, Soran H, Greenstein A, Loudon AS, Bechtold DA, Ray DW., Adiponectin induces A20 expression in adipose tissue to confer metabolic benefit. Diabetes 2015;64:128-136. doi: 10.2337/db13-1835
204. Zhu LH, Wang A, Luo P, Wang X, Jiang DS, Deng W, Zhang X, Wang T, Liu Y, Gao L, Zhang S, Zhang X, Zhang J, Li H., Mindin/Spondin 2 inhibits hepatic steatosis, insulin resistance, and obesity via interaction with peroxisome proliferator-activated receptor α in mice. J Hepatol 2014;60:1046-1054. doi: 10.1016/j.jhep.2014.01.011
205. Magalhaes JG, Lee J, Geddes K, Rubino S, Philpott DJ, Girardin SE., Essential role of Rip2 in the modulation of innate and adaptive immunity triggered by Nod1 and Nod2 ligands. Eur J Immunol 2011;41:1445-1455. doi: 10.1002/eji.201040827
206. Wang XA, Deng S, Jiang D, Zhang R, Zhang S, Zhong J, Yang L, Wang T, Hong S, Guo S, She Z, Zhang XD, Li H., CARD3 deficiency exacerbates diet-induced obesity, hepatosteatosis, and insulin resistance in male mice. Endocrinology 2013;154:685-697. doi: 10.1210/en.2012-1911
207. Hansson GK., Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-1695. doi: 10.1056/NEJMra043430
208. Hirata Y, Kurobe H, Higashida M, Fukuda D, Shimabukuro M, Tanaka K, Higashikuni Y, Kitagawa T, Sata M., HMGB1 plays a critical role in vascular inflammation and lesion formation via toll-like receptor 9. Atherosclerosis 2013;231:227-233. doi: 10.1016/j.atherosclerosis.2013.09.010
209. Schoneveld AH, Oude Nijhuis MM, van Middelaar B, Laman JD, de Kleijn DP, Pasterkamp G., Toll-like receptor 2 stimulation induces intimal hyperplasia and atherosclerotic lesion development. Cardiovasc Res 2005;66:162-169. doi: 10.1016/j.cardiores.2004.12.016
210. Michelsen KS, Doherty TM, Shah PK, Arditi M., TLR signaling: An emerging bridge from innate immunity to atherogenesis. J Immunol 2004;173:5901-5907.
211. Curtiss LK, Black AS, Bonnet DJ, Tobias PS., Atherosclerosis induced by endogenous and exogenous toll-like receptor (TLR)1 or TLR6 agonists. J Lipid Res 2012;53:2126-2132. doi: 10.1194/jlr.M028431
212. den Dekker WK, Cheng C, Pasterkamp G, Duckers HJ., Toll like receptor 4 in atherosclerosis and plaque destabilization. Atherosclerosis 2010;209:314-320. doi: 10.1016/j.atherosclerosis.2009.09.075
213. Cole JE, Navin TJ, Cross AJ, Goddard ME, Alexopoulou L, Mitra AT, Davies AH, Flavell RA, Feldmann M, Monaco C., Unexpected protective role for Toll-like receptor 3 in the arterial wall. Proc Natl Acad Sci U S A 2011;108:2372-2377. doi: 10.1073/pnas.1018515108
214. Salagianni M, Galani IE, Lundberg AM, Toll-like receptor 7 protects from atherosclerosis by constraining "inflammatory" macrophage activation. Circulation 2012;126:952-962. doi: 10.1161/CIRCULATIONAHA.111.067678
215. Engel D, Seijkens T, Poggi M, Sanati M, Thevissen L, Beckers L, Wijnands E, Lievens D, Lutgens E., The immunobiology of CD154-CD40-TRAF interactions in atherosclerosis. Semin Immunol 2009;21:308-312. doi: 10.1016/j.smim.2009.06.004
216. Zirlik A, Bavendiek U, Libby P, MacFarlane L, Gerdes N, Jagielska J, Ernst S, Aikawa M, Nakano H, Tsitsikov E, Schönbeck U., TRAF-1, -2, -3, -5, and -6 are induced in atherosclerotic plaques and differentially mediate proinflammatory functions of CD40L in endothelial cells. Arterioscler Thromb Vasc Biol 2007;27:1101-1107. doi: 10.1161/ATVBAHA.107.140566
217. Urbich C, Mallat Z, Tedgui A, Clauss M, Zeiher AM, Dimmeler S., Upregulation of TRAF-3 by shear stress blocks CD40-mediated endothelial activation. J Clin Invest 2001;108:1451-1458. doi: 10.1172/JCI13620
218. Wang AB, Li HL, Zhang R, She ZG, Chen HZ, Huang Y, Liu DP, Liang CC., A20 attenuates vascular smooth muscle cell proliferation and migration through blocking PI3k/Akt singling in vitro and in vivo. J Biomed Sci 2007;14:357-371. doi: 10.1007/s11373-007-9150-x
219. Longo CR, Arvelo MB, Patel VI, Daniel S, Mahiou J, Grey ST, Ferran C., A20 protects from CD40-CD40 ligand-mediated endothelial cell activation and apoptosis. Circulation 2003;108:1113-1118. doi: 10.1161/01.CIR.0000083718.76889.D0
220. Wolfrum S, Teupser D, Tan M, Chen KY, Breslow JL., The protective effect of A20 on atherosclerosis in apolipoprotein E-deficient mice is associated with reduced expression of NF-κB target genes. Proc Natl Acad Sci U S A 2007;104:18601-18606. doi: 10.1073/pnas.0709011104
221. Li HL, Wang AB, Zhang R, Wei YS, Chen HZ, She ZG, Huang Y, Liu DP, Liang CC., A20 inhibits oxidized low-density lipoprotein-induced apoptosis through negative Fas/Fas ligand-dependent activation of caspase-8 and mitochondrial pathways in murine RAW264.7 macrophages. J Cell Physiol 2006;208:307-318. doi: 10.1002/jcp.20665
222. Moll HP, Lee A, Minussi DC, da Silva CG, Csizmadia E, Bhasin M, Ferran C., A20 regulates atherogenic interferon (IFN)-γ signaling in vascular cells by modulating basal IFNβ levels. J Biol Chem 2014;289:30912-30924. doi: 10.1074/jbc.M114.591966
223. Zhu LH, Huang L, Zhang X, Zhang P, Zhang SM, Guan H, Zhang Y, Zhu XY, Tian S, Deng K, Li H., Mindin regulates vascular smooth muscle cell phenotype and prevents neointima formation. Clin Sci (Lond) 2015;129:129-145. doi: 10.1042/CS20140679
224. von Kampen O, Lipinski S, Till A, Martin SJ, Nietfeld W, Lehrach H, Schreiber S, Rosenstiel P., Caspase recruitment domain-containing protein 8 (CARD8) negatively regulates NOD2-mediated signaling. J Biol Chem 2010;285:19921-19926. doi: 10.1074/jbc.M110.127480
225. Paramel GV, Folkersen L, Strawbridge RJ, Elmabsout AA, Särndahl E, Lundman P, Jansson JH, Hansson GK, Sirsjö A, Fransén K., CARD8 gene encoding a protein of innate immunity is expressed in human atherosclerosis and associated with markers of inflammation. Clin Sci (Lond) 2013;125:401-407. doi: 10.1042/CS20120572
226. Hofmann U, Ertl G, Frantz S., Toll-like receptors as potential therapeutic targets in cardiac dysfunction. Expert Opin Ther Targets 2011;15:753-765. doi: 10.1517/14728222.2011.566560
227. Jiang DS, Zhang XF, Gao L, Zong J, Zhou H, Liu Y, Zhang Y, Bian ZY, Zhu LH, Fan GC, Zhang XD, Li H., Signal regulatory protein-α protects against cardiac hypertrophy via the disruption of toll-like receptor 4 signaling. Hypertension 2014;63:96-104. doi: 10.1161/HYPERTENSIONAHA.113.01506
228. Ha T, Li Y, Hua F, Ma J, Gao X, Kelley J, Zhao A, Haddad GE, Williams DL, William Browder I, Kao RL, Li C., Reduced cardiac hypertrophy in toll-like receptor 4-deficient mice following pressure overload. Cardiovasc Res 2005;68:224-234. doi: 10.1016/j.cardiores.2005.05.025
229. Dange RB, Agarwal D, Masson GS, Vila J, Wilson B, Nair A, Francis J., Central blockade of TLR4 improves cardiac function and attenuates myocardial inflammation in angiotensin II-induced hypertension. Cardiovasc Res 2014;103:17-27. doi: 10.1093/cvr/cvu067
230. Satoh M, Akatsu T, Ishikawa Y, Minami Y, Takahashi Y, Nakamura M., Association between toll-like receptor 8 expression and adverse clinical outcomes in patients with enterovirus-associated dilated cardiomyopathy. Am Heart J 2007;154:581-588. doi: 10.1016/j.ahj.2007.05.010
231. Zhang P, Cox CJ, Alvarez KM, Cunningham MW., Cutting edge: Cardiac myosin activates innate immune responses through TLRs. J Immunol 2009;183:27-31. doi: 10.4049/jimmunol.0800861
232. Wang H, Xu X, Fassett J, Kwak D, Liu X, Hu X, Falls TJ, Bell JC, Li H, Bitterman P, Bache RJ, Chen Y., Double-stranded RNA-dependent protein kinase deficiency protects the heart from systolic overload-induced congestive heart failure. Circulation 2014;129:1397-1406. doi: 10.1161/CIRCULATIONAHA.113.002209
233. Cook SA, Novikov MS, Ahn Y, Matsui T, Rosenzweig A., A20 is dynamically regulated in the heart and inhibits the hypertrophic response. Circulation 2003;108:664-667. doi: 10.1161/01.CIR.0000086978.95976.41
234. Huang H, Tang QZ, Wang AB, Chen M, Yan L, Liu C, Jiang H, Yang Q, Bian ZY, Bai X, Zhu LH, Wang L, Li H., Tumor suppressor A20 protects against cardiac hypertrophy and fibrosis by blocking transforming growth factor-beta-activated kinase 1-dependent signaling. Hypertension 2010;56:232-239. doi: 10.1161/HYPERTENSIONAHA.110.149963
235. Li HL, Zhuo ML, Wang D, Wang AB, Cai H, Sun LH, Yang Q, Huang Y, Wei YS, Liu PP, Liu DP, Liang CC., Targeted cardiac overexpression of A20 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circulation 2007;115:1885-1894. doi: 10.1161/CIRCULATIONAHA.106.656835
236. Suzuki S, Zhou Y, Refaat A, Takasaki I, Koizumi K, Yamaoka S, Tabuchi Y, Saiki I, Sakurai H., Human T cell lymphotropic virus 1 manipulates interferon regulatory signals by controlling the TAK1-IRF3 and IRF4 pathways. J Biol Chem 2010;285:4441-4446. doi: 10.1074/jbc.M109.031476
237. Zile MR, Brutsaert DL., New concepts in diastolic dysfunction and diastolic heart failure: Part II: Causal mechanisms and treatment. Circulation 2002;105:1503-1508.
238. Yan L, Wei X, Tang QZ, Cardiac-specific mindin overexpression attenuates cardiac hypertrophy via blocking AKT/GSK3β and TGF-β1-Smad signalling. Cardiovasc Res 2011;92:85-94. doi: 10.1093/cvr/cvr159
239. Bian ZY, Wei X, Deng S, Disruption of mindin exacerbates cardiac hypertrophy and fibrosis. J Mol Med (Berl) 2012;90:895-910. doi: 10.1007/s00109-012-0883-2
240. Zhang G, Ghosh S., Negative regulation of toll-like receptor-mediated signaling by Tollip. J Biol Chem 2002;277:7059-7065. doi: 10.1074/jbc.M109537200
241. Hu Y, Li T, Wang Y, Li J, Guo L, Wu M, Shan X, Que L, Ha T, Chen Q, Kelley J, Li Y., Tollip attenuated the hypertrophic response of cardiomyocytes induced by IL-1beta. Front Biosci (Landmark Ed) 2009;14:2747-2756.
242. Liu Y, Jiang XL, Liu Y, Jiang DS, Zhang Y, Zhang R, Chen Y, Yang Q, Zhang XD, Fan GC, Li H., Toll-interacting protein (Tollip) negatively regulates pressure overload-induced ventricular hypertrophy in mice. Cardiovasc Res 2014;101:87-96. doi: 10.1093/cvr/cvt232
243. Dufner A, Mak TW., CARD tricks: Controlling the interactions of CARD6 with RICK and microtubules. Cell Cycle 2006;5:797-800.
244. Li L, Chen W, Zhu Y, Wang X, Jiang DS, Huang F, Wang L, Xiang F, Qin W, Wang Q, Zhang R, Zhu X, Li H, Chen X., Caspase recruitment domain 6 protects against cardiac hypertrophy in response to pressure overload. Hypertension 2014;64:94-102. doi: 10.1161/HYPERTENSIONAHA.113.03021
245. Oyama J, Blais C Jr, Liu X, Pu M, Kobzik L, Kelly RA, Bourcier T., Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation 2004;109:784-789. doi: 10.1161/01.CIR.0000112575.66565.84
246. Shichita T, Sakaguchi R, Suzuki M, Yoshimura A., Post-ischemic inflammation in the brain. Front Immunol 2012;3:132. doi: 10.3389/fimmu.2012.00132
247. Ziegler G, Harhausen D, Schepers C, Hoffmann O, Röhr C, Prinz V, König J, Lehrach H, Nietfeld W, Trendelenburg G., TLR2 has a detrimental role in mouse transient focal cerebral ischemia. Biochem Biophys Res Commun 2007;359:574-579. doi: 10.1016/j.bbrc.2007.05.157
248. Hua F, Ma J, Ha T, Kelley JL, Kao RL, Schweitzer JB, Kalbfleisch JH, Williams DL, Li C., Differential roles of TLR2 and TLR4 in acute focal cerebral ischemia/reperfusion injury in mice. Brain Res 2009;1262:100-108. doi: 10.1016/j.brainres.2009.01.018
249. Vartanian KB, Stevens SL, Marsh BJ, Williams-Karnesky R, Lessov NS, Stenzel-Poore MP., LPS preconditioning redirects TLR signaling following stroke: TRIF-IRF3 plays a seminal role in mediating tolerance to ischemic injury. J Neuroinflammation 2011;8:140. doi: 10.1186/1742-2094-8-140
250. Hua F, Ma J, Ha T, Kelley J, Williams DL, Kao RL, Kalbfleisch JH, Browder IW, Li C., Preconditioning with a TLR2 specific ligand increases resistance to cerebral ischemia/reperfusion injury. J Neuroimmunol 2008;199:75-82. doi: 10.1016/j.jneuroim.2008.05.009
251. Stevens SL, Ciesielski TM, Marsh BJ, Yang T, Homen DS, Boule JL, Lessov NS, Simon RP, Stenzel-Poore MP., Toll-like receptor 9: A new target of ischemic preconditioning in the brain. J Cereb Blood Flow Metab 2008;28:1040-1047. doi: 10.1038/sj.jcbfm.9600606
252. Brea D, Sobrino T, Rodríguez-Yáñez M, Ramos-Cabrer P, Agulla J, Rodríguez-González R, Campos F, Blanco M, Castillo J., Toll-like receptors 7 and 8 expression is associated with poor outcome and greater inflammatory response in acute ischemic stroke. Clin Immunol 2011;139:193-198. doi: 10.1016/j.clim.2011.02.001
253. Hyakkoku K, Hamanaka J, Tsuruma K, Shimazawa M, Tanaka H, Uematsu S, Akira S, Inagaki N, Nagai H, Hara H., Toll-like receptor 4 (TLR4), but not TLR3 or TLR9, knock-out mice have neuroprotective effects against focal cerebral ischemia. Neuroscience 2010;171:258-267. doi: 10.1016/j.neuroscience.2010.08.054
254. Ellett JD, Evans ZP, Atkinson C, Schmidt MG, Schnellmann RG, Chavin KD., Toll-like receptor 4 is a key mediator of murine steatotic liver warm ischemia/reperfusion injury. Liver Transpl 2009;15:1101-1109. doi: 10.1002/lt.21782
255. Ben-Ari Z, Avlas O, Fallach R, Schmilovitz-Weiss H, Chepurko Y, Pappo O, Hochhauser E., Ischemia and reperfusion liver injury is reduced in the absence of Toll-like receptor 4. Cell Physiol Biochem 2012;30:489-498. doi: 10.1159/000341432
256. Jiang N, Zhang X, Zheng X, Chen D, Zhang Y, Siu LK, Xin HB, Li R, Zhao H, Riordan N, Ichim TE, Quan D, Jevnikar AM, Chen G, Min W., Targeted gene silencing of TLR4 using liposomal nanoparticles for preventing liver ischemia reperfusion injury. Am J Transplant 2011;11:1835-1844. doi: 10.1111/j.1600-6143.2011.03660.x
257. Ellett JD, Atkinson C, Evans ZP, Amani Z, Balish E, Schmidt MG, Schnellmann RG, Chavin KD., Toll-like receptor 4 knockout mice are protected from endothelial overactivation in the absence of Kupffer cells after total hepatic ischemia/reperfusion. Liver Transpl 2011;17:1089-1098. doi: 10.1002/lt.22333
258. Zhang J, Wu H, Wang L, Zhang J, Wang H, Zheng Q., TLR2 mRNA upregulation in ischemic lobes in mouse partial hepatic ischemia/reperfusion injury model. J Huazhong Univ Sci Technolog Med Sci 2004;24:144-146.
259. Zhang JX, Wu HS, Wang H, Zhang JH, Wang Y, Zheng QC., Protection against hepatic ischemia/reperfusion injury via downregulation of toll-like receptor 2 expression by inhibition of Kupffer cell function. World J Gastroenterol 2005;11:4423-4426.
260. Bamboat ZM, Balachandran VP, Ocuin LM, Obaid H, Plitas G, DeMatteo RP., Toll-like receptor 9 inhibition confers protection from liver ischemia-reperfusion injury. Hepatology 2010;51:621-632. doi: 10.1002/hep.23365
261. Lu C, Ren D, Wang X, Ha T, Liu L, Lee EJ, Hu J, Kalbfleisch J, Gao X, Kao R, Williams D, Li C., Toll-like receptor 3 plays a role in myocardial infarction and ischemia/reperfusion injury. Biochim Biophys Acta 2014;1842:22-31. doi: 10.1016/j.bbadis.2013.10.006
262. Mersmann J, Habeck K, Latsch K, Zimmermann R, Jacoby C, Fischer JW, Hartmann C, Schrader J, Kirschning CJ, Zacharowski K., Left ventricular dilation in toll-like receptor 2 deficient mice after myocardial ischemia/reperfusion through defective scar formation. Basic Res Cardiol 2011;106:89-98. doi: 10.1007/s00395-010-0127-y
263. Dong JW, Vallejo JG, Tzeng HP, Thomas JA, Mann DL., Innate immunity mediates myocardial preconditioning through Toll-like receptor 2 and TIRAP-dependent signaling pathways. Am J Physiol Heart Circ Physiol 2010 298 H1079 H1087. doi: 10.1152/ajpheart.00306.2009
264. Chen C, Feng Y, Zou L, Wang L, Chen HH, Cai JY, Xu JM, Sosnovik DE, Chao W., Role of extracellular RNA and TLR3-Trif signaling in myocardial ischemia-reperfusion injury. J Am Heart Assoc 2014 3 e000683. doi: 10.1161/JAHA.113.000683
265. Wang Y, Li C, Cheng K, Zhang R, Narsinh K, Li S, Li X, Qin X, Zhang R, Li C, Su T, Chen J, Cao F., Activation of liver X receptor improves viability of adipose-derived mesenchymal stem cells to attenuate myocardial ischemia injury through TLR4/NF-κB and Keap-1/Nrf-2 signaling pathways. Antioxid Redox Signal 2014;21:2543-2557. doi: 10.1089/ars.2013.5683
266. Chao W., Toll-like receptor signaling: A critical modulator of cell survival and ischemic injury in the heart. Am J Physiol Heart Circ Physiol 2009 296 H1 12. doi: 10.1152/ajpheart.00995.2008
267. Dhupar R, Klune JR, Evankovich J, Cardinal J, Zhang M, Ross M, Murase N, Geller DA, Billiar TR, Tsung A., Interferon regulatory factor 1 mediates acetylation and release of high mobility group box 1 from hepatocytes during murine liver ischemia-reperfusion injury. Shock 2011;35:293-301. doi: 10.1097/SHK.0b013e3181f6aab0
268. Lu YY, Li ZZ, Jiang DS, Wang L, Zhang Y, Chen K, Zhang XF, Liu Y, Fan GC, Chen Y, Yang Q, Zhou Y, Zhang XD, Liu DP, Li H., TRAF1 is a critical regulator of cerebral ischaemia-reperfusion injury and neuronal death. Nat Commun 2013;4:2852. doi: 10.1038/ncomms3852
269. Zhang XF, Zhang R, Huang L, Wang PX, Zhang Y, Jiang DS, Zhu LH, Tian S, Zhang XD, Li H., TRAF1 is a key mediator for hepatic ischemia/reperfusion injury. Cell Death Dis 2014 5 e1467. doi: 10.1038/cddis.2014.411
270. Wang L, Lu Y, Guan H, Jiang D, Guan Y, Zhang X, Nakano H, Zhou Y, Zhang Y, Yang L, Li H., Tumor necrosis factor receptor-associated factor 5 is an essential mediator of ischemic brain infarction. J Neurochem 2013;126:400-414. doi: 10.1111/jnc.12207
271. Sun J, Sun L, Zhang N, Lu X, Zhang H., A20 is up-regulated in primary mouse hepatocytes subjected to hypoxia and reperfusion. Cell Biochem Funct 2012;30:683-686. doi: 10.1002/cbf.2850
272. Ramsey HE, Da Silva CG, Longo CR, Csizmadia E, Studer P, Patel VI, Damrauer SM, Siracuse JJ, Daniel S, Ferran C., A20 protects mice from lethal liver ischemia/reperfusion injury by increasing peroxisome proliferator-activated receptor-alpha expression. Liver Transpl 2009;15:1613-1621. doi: 10.1002/lt.21879
273. Yu L, Miao H, Hou Y, Zhang B, Guo L., Neuroprotective effect of A20 on TNF-induced postischemic apoptosis. Neurochem Res 2006;31:21-32. doi: 10.1007/s11064-005-9004-8
274. Yu J, Lee HS, Lee SM, Yu HC, Moon WS, Chung MJ, Park JW, Park BH., Aggravation of post-ischemic liver injury by overexpression of A20, an NF-κB suppressor. J Hepatol 2011;55:328-336. doi: 10.1016/j.jhep.2010.11.029
275. Wan N, Liu X, Zhang XJ, Zhao Y, Hu G, Wan F, Zhang R, Zhu X, Xia H, Li H., Toll-interacting protein contributes to mortality following myocardial infarction through promoting inflammation and apoptosis. Br J Pharmacol 2015. doi: 10.1111/bph.13130
276. Nehyba J, Hrdlicková R, Bose HR., Dynamic evolution of immune system regulators: The history of the interferon regulatory factor family. Mol Biol Evol 2009;26:2539-2550. doi: 10.1093/molbev/msp167
277. Liu Y, Zhang YB, Liu TK, Gui JF., Lineage-specific expansion of IFIT gene family: An insight into coevolution with IFN gene family. PLoS One 2013 8 e66859. doi: 10.1371/journal.pone.0066859